CTAG2 and cancer: The highly homologous NY-ESO-1 and LAGE-1 (94%, nucleotide identity and 88% amino acid identity) are highly immunogenic, and a CTL response to an immunodominant, HLA-A2-restricted NY-ESO-1/LAGE-1 epitope can commonly be detected in cancer patients (29,30).